PMID- 17097874
OWN - NLM
STAT- MEDLINE
DCOM- 20070329
LR  - 20121115
IS  - 0960-7404 (Print)
IS  - 0960-7404 (Linking)
VI  - 15
IP  - 2
DP  - 2006 Aug
TI  - Alvocidib (Flavopiridol) suppresses tumor growth in SCID mice with human 
      esophageal cancer xenografts without inducing apoptosis.
PG  - 107-13
AB  - Alvocidib (Flavopiridol, HMR1275) is a potent inhibitor of multiple 
      cyclin-dependent kinases and has been identified recently as an antitumor agent 
      in several cancers. Previous studies have shown that alvocidib could potentially 
      treat esophageal cancer in vitro. This study evaluates alvocidib for its ability 
      to suppress tumor growth in severe combined immunodeficiency (SCID) mice bearing 
      TE8 human esophageal squamous cell carcinoma (SCC) xenografts. Alvocidib 
      treatment of 10mg/kg body weight reduced tumor volume significantly. 
      Immunohistochemistry analysis of alvocidib-treated tumor sections showed 
      significant reductions in cyclin D1, VEGF, and Rb levels. Alvocidib treatment did 
      not cause a marked increase in apoptotic tumor cells by terminal deoxynucleotidyl 
      transferase-mediated dUTP nick end labeling (TUNEL) analysis, yet hematoxylin and 
      eosin staining revealed tumor necrosis. In vivo investigation of alvocidib 
      treatment confirmed antitumor activity in TE8 esophageal xenografts. These 
      findings suggest that alvocidib could be a useful anti-cancer agent for 
      esophageal cancer.
FAU - Sato, Shinsuke
AU  - Sato S
AD  - Department of Gastroenterological Surgery, Juntendo University School of 
      Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. ssato@maz.miinet.or.jp
FAU - Kajiyama, Yoshiaki
AU  - Kajiyama Y
FAU - Sugano, Masahiko
AU  - Sugano M
FAU - Iwanuma, Yoshimi
AU  - Iwanuma Y
FAU - Sonoue, Hiroshi
AU  - Sonoue H
FAU - Matsumoto, Toshiharu
AU  - Matsumoto T
FAU - Tsurumaru, Masahiko
AU  - Tsurumaru M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20061113
PL  - Netherlands
TA  - Surg Oncol
JT  - Surgical oncology
JID - 9208188
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Flavonoids)
RN  - 0 (Piperidines)
RN  - 0 (Retinoblastoma Protein)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 136601-57-5 (Cyclin D1)
RN  - 45AD6X575G (alvocidib)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/pharmacology
MH  - *Apoptosis
MH  - Cell Line, Tumor
MH  - Cyclin D1/biosynthesis
MH  - Esophageal Neoplasms/*drug therapy/*genetics/*pathology
MH  - Female
MH  - Flavonoids/*pharmacology
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Nick-End Labeling
MH  - Mice
MH  - Mice, SCID
MH  - Necrosis
MH  - Neoplasm Transplantation
MH  - Piperidines/*pharmacology
MH  - Retinoblastoma Protein/biosynthesis
MH  - Vascular Endothelial Growth Factor A/biosynthesis
EDAT- 2006/11/14 09:00
MHDA- 2007/03/30 09:00
CRDT- 2006/11/14 09:00
PHST- 2006/08/27 00:00 [received]
PHST- 2006/10/02 00:00 [accepted]
PHST- 2006/11/14 09:00 [pubmed]
PHST- 2007/03/30 09:00 [medline]
PHST- 2006/11/14 09:00 [entrez]
AID - S0960-7404(06)00052-1 [pii]
AID - 10.1016/j.suronc.2006.10.001 [doi]
PST - ppublish
SO  - Surg Oncol. 2006 Aug;15(2):107-13. doi: 10.1016/j.suronc.2006.10.001. Epub 2006 
      Nov 13.